A Phase 4 interventional study of Semaglutide and Orlistat in Obesity, sponsored by Novo Nordisk A/S. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-14.
Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 143 studies testing semaglutide in Obesity — 68 open to participants now, 77 under way, 14 of them phase 3. Semaglutide · Obesity.
Among the 143 studies testing semaglutide in Obesity, this one is the 15th largest by enrollment, is one of 15 that started in 2023, is one of 40 in phase 4, and was the 54th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →68 of the 143 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Men only
McMaster University · Sites in Canada
Ages 18–60
Alain Dagher · Sites in Canada
Ages 35–55 · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 12–18
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18–65
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
143 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 24 · Phase 3 46 · Phase 4 40
First in 2014; this study’s year is marked. 15 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 500 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 100 across the 143 interventional studies. Of the 60 that completed or were terminated, 35 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 143 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
207 studies in Obesity by Novo Nordisk A/S: 48 open now, 66 under way, 26 of them phase 3. Of 138 finished, 39 (28%) have results posted.
Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 32nd largest by enrollment of the 166 interventional ones that give a count, is one of 21 that started in 2023, is one of 4 in phase 4, and was the 95th registered.
Novo Nordisk A/S’s Obesity studies by the year they started, since 2007.
22 of the studies testing semaglutide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07740291Texas Tech UniversityTirzepatide Impact Assessment Study | 2026-11-23 |
| NCT07430059Vivani Medical, IncSafety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant | 2026-12 |
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
| NCT06546384Insel Gruppe AG, University Hospital BernGLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease | 2026-12-31 |
| NCT05173714Srinvasan BeddhuSit Less, Interact and Move More (SLIMM) 2 Study | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 143 studies testing semaglutide in Obesity, from their registry updates:
Among Novo Nordisk A/S’s 207 in Obesity:
This tab as a report to print or save as PDF → With an account.
The purpose of this post approval pragmatic clinical study is to see how well semaglutide lowers body weight compared to other medication on the market used to treat obesity, across three US-based employers. These employers represent employees of diverse demography and job functions including hospitality, clerical, administrative, housekeeping, maintenance, and specialised employees across a range of socioeconomic and educational backgrounds. The study will also look at how weight loss affects physical functioning, quality of life and ability to work. It will also gather information on how satisfied participants are with the medication they take. Participants will either receive semaglutide or one of 4 approved anti-obesity medication (Xenical/Qsymia/Contrave/Saxenda).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive semaglutide 2.4 milligrams (mg) subcutaneous (s.c.) injection once weekly for 52 weeks as adjuncts to a reduced-calorie diet and increased physical activity for chronic weight management.
Drug: Semaglutide
Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks as adjuncts to a reduced-calorie diet and increased physical activity for chronic weight management. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
Drug: Orlistat · Drug: Phentermine/Topiramate · Drug: Naltrexone/Bupropion · Drug: Liraglutide
Participants will receive semaglutide 2.4 milligrams (mg) subcutaneous (s.c.) injection once weekly for 52 weeks.
Also known as: Wegovy
Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
Also known as: Xenical
Drug pages: Phentermine · Topiramate
Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
Also known as: Qsymia
Drug pages: Naltrexone · Bupropion
Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
Also known as: Contrave
Participants will receive one of 4 commercially available anti-obesity medication chosen by the study doctor for 52 weeks. The 4 anti-obesity medications are orlistat per os \[by mouth\] (p.o.), phentermine/topiramate extended release p.o., naltrexone/bupropion extended release p.o. or liraglutide 3.0 mg s.c injection.
Also known as: Saxenda
Number of Participants Who Achieved Greater Than or Equal to (≥) 10.0 Percent (%) Body Weight Reduction (Yes/no)
Number of participants who achieved greater than or equal to 10.0% body weight reduction (yes/no) at week 52 is presented.
Time frame: At end of treatment (week 52)
Percentage Change in Body Weight
Percentage change in body weight from week 0 to week 52 is presented.
Time frame: Baseline (week 0), end of treatment (week 52)
Change in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Domain
The IWQOL-Lite-CT is a 20-item, obesity-specific patient-reported outcome (PRO) instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items), and psychosocial (13 items). A 5-item subset of the physical domain, the physical-function composite is also supported. Items in the physical-function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better quality of life. This outcome measure shows results for physical function domain.
Time frame: Baseline (week 0), end of treatment (week 52)
Number of Participants Who Achieved Greater Than or Equal to (≥) 15.0% Body Weight Reduction (Yes/no)
Number of participants who achieved more than or equal to 15.0% body weight reduction (yes/no) at week 52 is presented.
Time frame: At end of treatment (week 52)
Number of Participants Who Achieved Greater Than or Equal to (≥) 20.0% Body Weight Reduction (Yes/no)
Number of participants who achieved more than or equal to 20.0% body weight reduction (yes/no) at week 52 is presented.
Time frame: At end of treatment (week 52)
Number of Participants Who Achieved Change in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Domain Score Greater Than or Equal to (≥) 14.6 (Yes/no)
The IWQOL-Lite-CT is a 20-item, obesity-specific patient-reported outcome (PRO) instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items), and psychosocial (13 items). A 5-item subset of the physical domain, the physical-function composite is also supported. Items in the physical-function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better quality of life. This outcome measure shows results for physical function domain score ≥ 14.6.
Time frame: At end of treatment (week 52)
Percentage of Days Covered (PDC) by Study Product
Percentage of days covered by study product from week 0 to week 52 is presented. The percentage of days covered by the study product is determined by the duration on the study product divided by the planned study duration, multiplied by 100.
Time frame: From week 0 to week 52
Number of Participants Covered by Study Product Greater Than or Equal to (≥) 80% of Days (Yes/no)
Number of participants covered by study product ≥80% of days (yes/no) from week 0 to week 52 is presented.
Time frame: At end of treatment (week 52)
Change in Work Limitations Questionnaire 25-item Version (WLQ-25), Total Score (TS)
Work Limitations Questionnaire (WLQ-25) is a 25-item questionnaire that measures how health problems affect job performance and productivity over the past two weeks, using a 5-point Likert scale. It covers four domains: Time Management (5 items), Physical Demands (6), Mental/Interpersonal (9), and Output Demands (5). Each item is scored from 1 to 5, with subscale scores calculated as the average item score, then converted to a 0-100 scale using the formula: WLQ Scale Score= 25 × (average item score - 1). Thus, each subscale ranges from 0 (no limitation) to 100 (maximum limitation). The WLQ total score is computed by applying specific weights to each subscale and summing them: 0.00048 × Time scale + 0.00036 × Physical scale + 0.00096 × Mental/Interpersonal scale + 0.00106 × Output scale. This total is then transformed into the proportion of productivity loss using the formula: (1 - exp(-total score)).
Time frame: Baseline (week 0), end of treatment (week 52)
The study was conducted at one site in United States.
| Milestone | Semaglutide 2.4 mg | Other Anti-obesity Medications (AOMs) |
|---|---|---|
| Started | 250 | 250 |
| Full analysis set | 250 | 250 |
| Safety analysis set | 242 | 242 |
| Completed | 214 | 191 |
| Not completed | 36 | 59 |
| Withdrew: Withdrawal by subject | 1 | 3 |
| Withdrew: Lost to follow-up | 33 | 52 |
| Withdrew: Physician decision | 2 | 2 |
| Withdrew: Death | 0 | 2 |
Number of participants who achieved greater than or equal to 10.0% body weight reduction (yes/no) at week 52 is presented.
| Participants | Semaglutide 2.4 mg | Other Anti-obesity Medications (AOMs) |
|---|---|---|
| Yes | 132 | 61 |
| No | 75 | 116 |
Percentage change in body weight from week 0 to week 52 is presented.
| Percentange change in body weight | Semaglutide 2.4 mg | Other Anti-obesity Medications (AOMs) |
|---|---|---|
| Percentage Change in Body Weight | -13.6 ± 8.7 | -7.4 ± 7.3 |
The IWQOL-Lite-CT is a 20-item, obesity-specific patient-reported outcome (PRO) instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items), and psychosocial (13 items). A 5-item subset of the physical domain, the physical-function composite is also supported. Items in the physical-function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better quality of life. This outcome measure shows results for physical function domain.
| Score on a scale | Semaglutide 2.4 mg | Other Anti-obesity Medications (AOMs) |
|---|---|---|
| Change in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Domain | 25.6 ± 21.2 | 22.6 ± 24.4 |
Number of participants who achieved more than or equal to 15.0% body weight reduction (yes/no) at week 52 is presented.
| Participants | Semaglutide 2.4 mg | Other Anti-obesity Medications (AOMs) |
|---|---|---|
| Yes | 93 | 25 |
| No | 114 | 152 |
Number of participants who achieved more than or equal to 20.0% body weight reduction (yes/no) at week 52 is presented.
| Participants | Semaglutide 2.4 mg | Other Anti-obesity Medications (AOMs) |
|---|---|---|
| Yes | 49 | 8 |
| No | 158 | 169 |
The IWQOL-Lite-CT is a 20-item, obesity-specific patient-reported outcome (PRO) instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity-related health-related quality of life (HRQoL): physical (7 items), and psychosocial (13 items). A 5-item subset of the physical domain, the physical-function composite is also supported. Items in the physical-function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better quality of life. This outcome measure shows results for physical function domain score ≥ 14.6.
| Participants | Semaglutide 2.4 mg | Other Anti-obesity Medications (AOMs) |
|---|---|---|
| Yes | 138 | 108 |
| No | 51 | 55 |
Percentage of days covered by study product from week 0 to week 52 is presented. The percentage of days covered by the study product is determined by the duration on the study product divided by the planned study duration, multiplied by 100.
| Percentage of days covered | Semaglutide 2.4 mg | Other Anti-obesity Medications (AOMs) |
|---|---|---|
| Percentage of Days Covered (PDC) by Study Product | 83.7 ± 24.6 | 70.8 ± 28.6 |
Number of participants covered by study product ≥80% of days (yes/no) from week 0 to week 52 is presented.
| Participants | Semaglutide 2.4 mg | Other Anti-obesity Medications (AOMs) |
|---|---|---|
| Yes | 168 | 113 |
| No | 82 | 137 |
Work Limitations Questionnaire (WLQ-25) is a 25-item questionnaire that measures how health problems affect job performance and productivity over the past two weeks, using a 5-point Likert scale. It covers four domains: Time Management (5 items), Physical Demands (6), Mental/Interpersonal (9), and Output Demands (5). Each item is scored from 1 to 5, with subscale scores calculated as the average item score, then converted to a 0-100 scale using the formula: WLQ Scale Score= 25 × (average item score - 1). Thus, each subscale ranges from 0 (no limitation) to 100 (maximum limitation). The WLQ total score is computed by applying specific weights to each subscale and summing them: 0.00048 × Time scale + 0.00036 × Physical scale + 0.00096 × Mental/Interpersonal scale + 0.00106 × Output scale. This total is then transformed into the proportion of productivity loss using the formula: (1 - exp(-total score)).
| Score on a scale | Semaglutide 2.4 mg | Other Anti-obesity Medications (AOMs) |
|---|---|---|
| Change in Work Limitations Questionnaire 25-item Version (WLQ-25), Total Score (TS) | -0.034 ± 0.070 | -0.016 ± 0.048 |
Collected over From week 0 to week 52. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Semaglutide 2.4 mg | 0/250 (0%) | 3/242 (1.2%) | 0/242 (0%) |
| Other Anti-obesity Medications (AOMs) | 2/250 (0.8%) | 8/242 (3.3%) | 0/242 (0%) |
| Event | Semaglutide 2.4 mg | Other Anti-obesity Medications (AOMs) |
|---|---|---|
| CholecystitisHepatobiliary disorders | 0/242 | 2/242 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/242 | 2/242 |
| Amyotrophic lateral sclerosisNervous system disorders | 1/242 | 0/242 |
| Atrioventricular block completeCardiac disorders | 1/242 | 0/242 |
| Drug hypersensitivityImmune system disorders | 0/242 | 1/242 |
| Cardiac arrestCardiac disorders | 0/242 | 1/242 |
| DiverticulitisInfections and infestations | 0/242 | 1/242 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/242 | 1/242 |
| Suicide attemptPsychiatric disorders | 0/242 | 1/242 |
Full analysis set included all randomized participants.
| Age, Continuous(Years) | Semaglutide 2.4 mg | Other Anti-obesity Medications (AOMs) | Total |
|---|---|---|---|
| Mean | 40.6 ± 9.3 | 42.0 ± 10.3 | 41.3 ± 9.8 |
| Sex: Female, Male(Participants) | Semaglutide 2.4 mg | Other Anti-obesity Medications (AOMs) | Total |
|---|---|---|---|
| Female | 225 | 223 | 448 |
| Male | 25 | 27 | 52 |
| Ethnicity (NIH/OMB)(Participants) | Semaglutide 2.4 mg | Other Anti-obesity Medications (AOMs) | Total |
|---|---|---|---|
| Hispanic or Latino | 159 | 150 | 309 |
| Not Hispanic or Latino | 91 | 100 | 191 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Semaglutide 2.4 mg | Other Anti-obesity Medications (AOMs) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 10 | 8 | 18 |
| Asian | 17 | 7 | 24 |
| Native Hawaiian or Other Pacific Islander | 5 | 1 | 6 |
| Black or African American | 23 | 27 | 50 |
| White | 193 | 202 | 395 |
| More than one race | 2 | 5 | 7 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
Ran from Jan 2023 to primary completion in Nov 2024, 22 months.
Results were first posted in Jan 2026, 1 year 1 month after primary completion.
Of 210 phase 4 interventional studies under Obesity, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's 22 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide